Company
Tissue Regenix Group PLC
LON:TRX
Tissue Regenix Group PLC is a pioneering, international medical technology company, focusing on the development of regenerative products utilising its two platform technologies, dCELL, addressing soft tissue needs, and BioRinse, providing sterile bone allografts. The company is currently helping to transform the treatment of patients in key surgical applications: biosurgery, orthopaedics (sports medicine/spine), dental, general, plastic surgery, urology/gynaecology, ophthalmology and cardiac.
255 stories · page 3 of 13
Tissue Regenix inks German distribution deal
The company has negotiated a multi-year agreement with Hamburg-based 2med
Tissue Regenix on course for underlying profitability in Q4, says research house
The latest update from Hardman & Co lifts the lid on the progress of the regenerative medicines specialist
Tissue Regenix says first-half losses narrow on sales growth, cost management
Revenue for the company's BioRinse division jumped 32% to US$7.8mln
Tissue Regenix: Four-pronged strategy helping deliver on growth aspirations
If March’s prelims from Tissue Regenix (TRX) marked an inflexion point for the regenerative medical devices specialist, then it was largely missed by the wider investing public
Tissue Regenix 'well-positioned to deliver persistently strong sales growth', says analyst
Hardman's Dr Martin Hall provided a brief appraisal of prospects after the company's trading statement
Tissue Regenix confident of meeting full-year expectations after solid first half
The regenerative medical devices specialist said sales to June 30 were around US$11.8mln, up 25% year on year, or 27% at constant currencies
Tissue Regenix 'on a pathway to sustainability'
"Progress is forecast to continue in 2022, resulting in 22% sales growth, which will drive margin expansion towards profitability by the end of 2022," Hardman said.
Tissue Regenix eyes profitability after a year of double-digit growth
"Our organisation continued to demonstrate success despite all the ongoing challenges associated with the pandemic,” said chief Daniel Lee
Tissue Regenix Group inks Italian distribution deal for OrthoPure XT product
It is teaming up with Geistlich Biomaterials Italia, which will help advance the clinical science supporting the OrthoPure
Tissue Regenix 2021 performance lives up to management expectations
It battled the twin challenges of Covid disruption and foreign exchange ‘headwinds’
Tissue Regenix encouraged by recovery in elective surgery
“Market indications for a post-pandemic recovery are encouraging”
Tissue Regenix launches two line extensions using breakthrough dCELL technology
The company is bringing to the market DermaPure Meshed and VNEWTM
Tissue Regenix completes phase one of San Antonio expansion on time and on budget
The company announced on 18 March it had completed the initial part of its expansion project; now the rest of the phase one expansion is done and dusted
Tissue Regenix confident on post-COVID-19 prospects
The capacity expansion programme will alleviate the supply issues that have previously hindered growth and will provide a step-change in the business trajectory, the firm said
Tissue Regenix says Texas expansion plans are on track
Work thus far has focused on relocating distribution operations and frozen tissue storage
Tissue Regenix highlights strong 2020 performance despite pandemic challenges
For the year to December 31, the regenerative medicine specialist said revenues for the year will be £12.8mln, in line with the prior-year figure despite the impact of the pandemic, adding that it also ended the period with a “strong cash p
Tissue Regenix announces appointment of David Cocke as its chief financial officer with immediate effect
Cocke has over 29 years of experience in the medical device industry holding senior finance and operations positions and In 1997, he founded NuPak Medical, an ISO-certified contract manufacturer of sterile disposable medical device